News


All series


All News

Confirming the results of an earlier phase II study, findings from the FALCON trial showed first-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with hormone receptor (HR)-positive advanced breast cancer.

Atezolizumab has received FDA approval for the treatment of patients with metastatic NSCLC who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring <em>EGFR</em> or <em>ALK</em> abnormalities.&nbsp;

<em>Targeted Oncology</em> speaks with Shaji Kumar, MD, to understand the roles that the new criteria for response and minimal residual disease (MRD) assessment in multiple myeloma&nbsp;and what role MRD testing will play going forward in multiple myeloma.<br /> &nbsp;